First-line erlotinib therapy until and beyond response evaluation criteria in solid tumors progression in Asian patients with epidermal growth factor receptor mutation-positive non-small-cell lung cancer the ASPIRATION study

JAMA Oncology

Volumn 2, Issue 3, 2016, Pages 305-312

  Park, Keunchil ^a   Yu, Chong Jen ^b   Kim, Sang We ^c   Lin, Meng Chih ^d,e   Sriuranpong, Virote ^f   Tsai, Chun Ming ^g,h   Lee, Jong Seok ⁱ   Kang, Jin Hyoung ^j   Chan, K C Allen ^k   Perez Moreno, Pablo ^l   Button, Peter ^m   Ahn, Myung Ju ^a   Mok, Tony ^k  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c University of Ulsan College of Medicine   (South Korea)

^d CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^e CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^f CHULALONGKORN UNIVERSITY   (Thailand)

^g TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^h NATIONAL YANG MING UNIVERSITY   (Taiwan)

ⁱ Seoul National University Bundang Hospital   (South Korea)

^j The Catholic University of Korea   (South Korea)

^k CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^l F HOFFMANN LA ROCHE LTD   (Switzerland)

^m Roche Products Pty Ltd   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; PROTEIN KINASE INHIBITOR;

ADULT; AGED; ANTAGONISTS AND INHIBITORS; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; DISEASE FREE SURVIVAL; FEMALE; GENETICS; HUMAN; LUNG NEOPLASMS; MALE; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MUTATION; ORAL DRUG ADMINISTRATION; PATHOLOGY; PHASE 2 CLINICAL TRIAL; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; VERY ELDERLY;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; ERLOTINIB HYDROCHLORIDE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;

EID: 84979503381     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2015.4921     Document Type: Article

References (24)

1. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350(21): 2129-2139.
2. Paez JG, Jänne PA, Lee JC, et al. EGFRmutations in lung cancer: correlationwith clinical response to gefitinib therapy. Science. 2004;304(5676):1497-1500.
3. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947-957.
4. Han JY, Park K, Kim SW, et al. First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokerswith adenocarcinoma of the lung. J Clin Oncol. 2012;30(10):1122-1128.
5. Mitsudomi T, Morita S, Yatabe Y, et al; West Japan Oncology Group. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010; 11(2):121-128.
6. Maemondo M, Inoue A, Kobayashi K, et al; North-East Japan Study Group. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362(25):2380-2388.
7. Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011;12 (8):735-742.
8. Costa C, Molina MA, Drozdowskyj A, et al. The impact of EGFR T790M mutations and BIM mRNA expression on outcome in patients with EGFR-mutant NSCLC treated with erlotinib or chemotherapy in the randomized phase III EURTAC trial. Clin Cancer Res. 2014;20(7):2001-2010.
9. Sequist LV, Yang JC, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013;31(27):3327-3334.
10. Jackman D, Pao W, Riely GJ, et al. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J Clin Oncol. 2010;28(2): 357-360.
11. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981; 47(1):207-214.
12. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumours. J Natl Cancer Inst. 2000;92(3):205-216.
13. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228-247.
14. Yun CH, Mengwasser KE, Toms AV, et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci U S A. 2008;105(6):2070-2075.
15. Riely GJ, Kris MG, Zhao B, et al. Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus. Clin Cancer Res. 2007;13 (17):5150-5155.
16. Oxnard GR, Lo P, Jackman DM, et al. Delay of chemotherapy through use of post-progression erlotinib in patients with EGFR mutant lung cancer. J Clin Oncol. 2012;30(suppl):abstr 7547.
17. Nishie K, Kawaguchi T, Tamiya A, et al. Epidermal growth factor receptor tyrosine kinase inhibitors beyond progressive disease: a retrospective analysis for Japanese patients with activating EGFR mutations. J Thorac Oncol. 2012;7 (11):1722-1727.
18. NCCN Guidelines Version 1.2015. Non-Small Cell Lung Cancer. National Comprehensive Cancer Network website. http://www.nccn.org/professionals/physician-gls/f-guidelines.asp. Accessed June 11, 2015.
19. Ou SH, Jänne PA, Bartlett CH, et al. Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC. Ann Oncol. 2014;25 (2):415-422.
20. Kim Y, Ko J, Cui Z, et al. The EGFR T790M mutation in acquired resistance to an irreversible second-generation EGFR inhibitor. Mol Cancer Ther. 2012;11(3):784-791.
21. Soria J, Wu Y, Nakagawa K, et al. Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial. Lancet Oncol. 2015;16(8):990-998.
22. Oxnard GR, Arcila ME, Sima CS, et al. Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation. Clin Cancer Res. 2011;17(6):1616-1622.
23. Wu YL, Lee JS, Thongprasert S, et al. Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial. Lancet Oncol. 2013;14(8):777-786.
24. Mok T, Wu YL, Lee JS, et al. Detection and dynamic changes of EGFR mutations from circulating tumour DNA as a predictor of survival outcomes in NSCLC patients treated with first-line intercalated erlotinib and chemotherapy. Clin Cancer Res. 2015;21(14):3196-3203.